The study is ongoing, and future analyses will include survival outcomes, researchers say. Adding TAR-200 to neoadjuvant treatment with cetrelimab can improve the pathologic complete response (pCR) ...

MMRd showed no meaningful association with pOR, pCR, or RFS, suggesting limited utility for selecting patients for Gem-iDRS ...

In the neoadjuvant setting, the gemcitabine intravesical drug delivery system (TAR-200) improved immune checkpoint inhibition with comparable safety in patients with muscle-invasive bladder cancer ...

Since March 2025, the adoption of neoadjuvant and adjuvant immunotherapy-based regimens have shifted the traditional paradigm of cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical ...

SunRISe-4 evaluated neoadjuvant gemcitabine intravesical system (TAR-200) plus cetrelimab or cetrelimab monotherapy for pathologic complete response in patients with MIBC ineligible for or refusing ...

Please provide your email address to receive an email when new articles are posted on . Most patients with non-muscle-invasive bladder cancer who received TAR-200 with gemcitabine achieved complete ...

Safety and efficacy of the erdafitinib (erda) intravesical delivery system, TAR-210, in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) ...

Pfizer has linked its PD-1 inhibitor to a 32% reduction in the risk of disease-related events in a phase 3 bladder cancer trial. But the study fell short of a clean sweep of positive outcomes, with ...

A multicenter, randomized, phase 2, investigator-initiated ETCTN trial of olaparib + radium-223 vs. radium-223 in men with castration-resistant prostate cancer (CRPC) with bone metastases (BM) ...